CIK 0001427570
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Vyome Holdings, Inc
Sign in to watch- Ticker
- HIND
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 949-429-6680
- Business address
- 1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673
- Former names
- ReShape Lifesciences Inc., OBALON THERAPEUTICS INC
- 4 Open-market sale Chief Financial Officer sold 3,684 shares at $1.22 ($4,494)
- 4 Open-market sale President and CEO sold 7,150 shares at $1.79 ($12,799)
- 4 Open-market sale Chief Financial Officer sold 3,171 shares at $1.78 ($5,644)
- 4 Open-market sale President and CEO sold 13,427 shares at $1.83 ($24,571)
- 4 Open-market sale Chief Financial Officer sold 4,304 shares at $1.83 ($7,863)
- 4 Open-market buy Chief Financial Officer bought 20,000 shares at $2.02 ($40,400)
- 4 Open-market sale President and CEO sold 13,505 shares at $2.69 ($36,328)
- 4 Open-market sale Chief Financial Officer sold 4,320 shares at $2.69 ($11,621)
- 4 Open-market sale Chief Financial Officer sold 3,660 shares at $2.76 ($10,102)
- 4 Open-market sale President and CEO sold 12,565 shares at $2.77 ($34,805)
- 4 Open-market sale President and CEO sold 294,494 shares at $2.89 ($851,088)
- 4 Open-market sale Chief Financial Officer sold 48,366 shares at $2.89 ($139,778)
- 4 Open-market sale Director sold 200,000 shares at $2.99 ($598,000)
- 4 Grant or award Director acquired 253,429 shares (grant or award)
- 4 Grant or award Director acquired 253,429 shares (grant or award)
- 4 Grant or award Director acquired 253,429 shares (grant or award)
- 4 Open-market buy Chief Financial Officer bought 15,000 shares at $3.43 ($51,435)
- 4 Open-market buy Chief Financial Officer bought 15,000 shares at $3.22 ($48,285)
- 4 Option exercise 10% owner acquired 7,130,806 shares (option exercise)
- 3 Insider Initial Statement of Ownership
Page 3 of 13 · 243 filings